Search
Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests
In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.
Read moreEU Parliament agrees on pharmaceutical legislation stance
On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.
Read moreEHA Mentorship Program eligibility
Before applying for the EHA Mentorship Program, please consider the eligibility criteria on this page. You should also read our policy on life events.
Read moreNon-EHA Funding Opportunities
Here you will find other interesting funding opportunities for European researchers in hematology. If you are interested in adding additional opportunities to this page, please contact research@ehaweb. org.
Read moreMadrid Declaration: joint call for action on training requirements
The Madrid Declaration on enhanced training requirements for hematologists in the Professional Qualifications Directive enjoyed broad support from national society representatives at the EHA22 National Societies Dinner in Madrid.
Read moreA well-attended second meeting from the European Hematology Association (EHA) and the EHA Scientific Working Group on Red Cell and Iron
For the second time the European Hematology Association (EHA) and the EHA Scientific Working Group on Red Cell and Iron joined in the organization of the meeting focused on Red Cell and Iron Metabolism Defects: From basic science to clinical…
Read moreGranulocytes & Constitutional Marrow Failures Disorders
The Specialized Working Group (SWG) on Granulocytes and Constitutional Marrow Failure Syndromes (G&CMFS) derives from the fusion of the formerly existing SWG on Granulocyte and Monocyte Disorders with other initiatives, grown within the EHA environment, related to Constitutional Marrow Failure…
Read moreMission
The European Hematology Association (EHA) promotes excellence in patient care, research, and education in hematology.
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- »